Listen Top Shows Blog

Inavolisib in Endocrine Resistant PIK3CA Mutated HR+, HER2- Breast Cancer with Dr. Kasia Jerzak

Inavolisib in Endocrine Resistant PIK3CA Mutated HR+, HER2- Breast Cancer with Dr. Kasia Jerzak

Update: 2025-10-07

Share

Description

As we now have access to Inavolisib via a ROCHE sponsored PSP for the first line treatment of endocrine resistant HR+ HER2- PIK3CA altered breast cancer progressing on or after adjuvant endocrine therapy, Dr. Kasia Jerzak takes us through the regimen, its practical use and efficacy and toxicity management.

Comments

In Channel

BREAKWATER: Charting New Waters in Advanced BRAFmt CRC with Dr. Rachel Goodwin

BREAKWATER: Charting New Waters in Advanced BRAFmt CRC with Dr. Rachel Goodwin

2025-11-2434:54

Inavolisib in Endocrine Resistant PIK3CA Mutated HR+, HER2- Breast Cancer with Dr. Kasia Jerzak

Inavolisib in Endocrine Resistant PIK3CA Mutated HR+, HER2- Breast Cancer with Dr. Kasia Jerzak

2025-10-0732:58

TDXD a new DESTINY for HER2+ Gastro/GEJ adeno in 2nd line with Dr. Brezden-Masley

TDXD a new DESTINY for HER2+ Gastro/GEJ adeno in 2nd line with Dr. Brezden-Masley

2025-09-1636:13

Check or Checkmate Ipi/Nivo in HCC with Dr. Hatim Karachiwala

Check or Checkmate Ipi/Nivo in HCC with Dr. Hatim Karachiwala

2025-09-1132:53

IPI/NIVO for mCRC with Dr. Sharlene Gill

IPI/NIVO for mCRC with Dr. Sharlene Gill

2025-08-2133:23

The CHALLENGE to Move and Survive: Exercise After Adjuvant Colon Cancer Treatment with Dr. Christopher Booth

The CHALLENGE to Move and Survive: Exercise After Adjuvant Colon Cancer Treatment with Dr. Christopher Booth

2025-08-1130:11

Amivantamab + Lazertinib in 1st line Advanced EGFR + NSCLC - Mariposa

Amivantamab + Lazertinib in 1st line Advanced EGFR + NSCLC - Mariposa

2025-06-0250:12

Claudin 18.2 - a SPOTLIGHT on Zolbetuximab - Part 2 of 2

Claudin 18.2 - a SPOTLIGHT on Zolbetuximab - Part 2 of 2

2025-05-1639:42

Claudin 18.2 - a GLOW-ing biomarker in Gastric Cancer - Part 1 of 2

Claudin 18.2 - a GLOW-ing biomarker in Gastric Cancer - Part 1 of 2

2025-05-0649:41

Take 2 Aspirin and call me in the morning - Adjuvant therapy for Colorectal Cancer

Take 2 Aspirin and call me in the morning - Adjuvant therapy for Colorectal Cancer

2025-03-2735:18

Resectable NSCLC: How to Choose the Right Treatment

Resectable NSCLC: How to Choose the Right Treatment

2025-03-0345:35

2L Treatment of EGFR-Positive NSCLC

2L Treatment of EGFR-Positive NSCLC

2025-02-1838:40

Belzutifan - A Spark of Light for Clear Cell Renal Cell Carcinoma

Belzutifan - A Spark of Light for Clear Cell Renal Cell Carcinoma

2025-01-3141:49

00:00

00:00

1.0x

Inavolisib in Endocrine Resistant PIK3CA Mutated HR+, HER2- Breast Cancer with Dr. Kasia Jerzak

Inavolisib in Endocrine Resistant PIK3CA Mutated HR+, HER2- Breast Cancer with Dr. Kasia Jerzak